Published date: Oct 04 2024

Journal Title: KnE Life Sciences

Issue title: 4th International Conference in Social Science (4th ICONISS): Healthcare

Pages: 163–174

DOI: 10.18502/kls.v8i2.17369

Arief KurniawanDepartment of Anesthesia, Faculty of Medicine, Jenderal Achmad Yani University, Cimahi

Anastasia Yani TriningtyasDepartment of Public Health Sciences, Faculty of Medicine, Jenderal Achmad Yani University, Cimahi

Adriel Daviddavidtigorbutar@gmail.comDepartment of Medicine, Faculty of Medicine, Jenderal Achmad Yani University, Cimahi

The 2019 coronavirus disease was declared a pandemic by the World Health Organization in March 2020. By 2021, Indonesia had a total of 4,262,720 cases and 142,560 deaths. By 2021, the total number of confirmed COVID-19 cases grew to 4,262,720. Since the deaths due to the coronavirus amounted to 144,094, clinical manifestations in patients with COVID-19 have a wide spectrum, ranging from no to severe symptoms. Most patients have symptoms such as fever, cough, sneezing, and shortness of breath. Age, gender, accompanying diseases, clinical symptoms, and laboratory parameters are all related to the duration of treatment for COVID-19 patients; comorbidities can cause complications such as hypertension, heart disease, chronic kidney disease, and chronic lung disease. The research draft used in this study is descriptive. Previous research showed that the age of most participants (55%) was 50 years and 59% were male, 91% had respiratory complaints, 90% had a respiratory cough, 94% had a non-respiratory fever, the treatment length was 6–11 days in 68%, bronchopulmonary pneumonia as a complication was seen in 43%, and comorbid hypertension was reported in 35%. The results of the study showed that elderly patients are at greater risk of getting infected with COVID-19, and respiratory complaints are the most common because COVID-19 attacks the reproductive organs, and fever is a manifestation of the infection of the body with the virus. Hypertension is the most common comorbidity that causes the activation of COVID-19 caused by ACE 2.

Keywords: Covid-19, primary complaint, treatment length, complication, comorbid

[1] MMWR. “MMWR - Characteristics of Health Care Personnel with COVID-19 — United States,” February 12–April 9, 2020. [Internet]. 2019. Available from: https://www.cdc.gov/coronavirus/2019-ncov/php/reporting-pui.html

[2] Sukirmana R, Muryantoa I, Malfasarib E, Mahkotac R. Karakteristik Epidemiologi COVID-19 Tahun 2020–2021: Studi Potong Lintang di Provinsi Riau. Jurnal Epidemiologi Kesehatan Indonesia. 2022;6(1):37–44.

[3] PEMANTAUAN COVID-19 KEMENTERIAN KESEHATAN REPUBLIK INDONESIA [Internet]. Available from: https://pusatkrisis.kemkes.go.id/covid-19-id/, last accessed 2023/05/16.

[4] Gomes C. Report of the WHO-China joint mission on coronavirus disease 2019 (COVID-19). Brazilian Journal of Implantology and health sciences. 2020;2(3).

[5] Ikawaty R. Dinamika interaksi reseptor ACE2 dan SARS-CoV-2 terhadap manifestasi klinis COVID-19. KELUWIH: Jurnal Kesehatan dan Kedokteran. 2020;1(2):67-73.

[6] Baihaqi FA, Rumaropen H. Faktor-Faktor yang Berhubungan dengan Lama Rawat Inap Pasien COVID-19 di RSUD Serui Provinsi Papua: Studi Potong Lintang. Jurnal Penyakit Dalam Indonesia. 2021;8(4):187–94.

[7] Komplikasi dan Kematian Akibat Covid-19 | Badan Penelitian dan Pengembangan Kesehatan [Internet]. Available from: https://www.litbang.kemkes.go.id/komplikasidan- kematian-akibat-covid-19/, last accessed 2022/10/09.

[8] Masdalena M, Muryanto I, Efendi AS, Yunita J, Gustina T. Faktor Risiko Komorbid pada Kematian Covid-19 di Rumah Sakit X Tahun 2021 [ JKMM]. Jurnal Kesehatan Masyarakat Mulawarman. 2021;3(2):105–17.

[9] Beniac DR, Andonov A, Grudeski E, Booth TF. Architecture of the SARS coronavirus prefusion spike. Nat Struct Mol Biol. 2006 Aug;13(8):751–2.

[10] Arianto D, Sutrisno A. Kajian antisipasi pelayanan kapal dan barang di pelabuhan pada masa pandemi Covid–19. Jurnal Penelitian Transportasi Laut. 2020;22(2):97– 110.

[11] Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Müller MA. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. cell. 2020;181(2):271-80.

[12] Rajnik M, Cascella M, Cuomo A, Dulebohn SC, Di Napoli R. Features, evaluation, and treatment of coronavirus (COVID-19). Uniformed Services University Of The Health Sciences. 2021 Mar 1.

[13] Nasution NH, Hidayah A. Gambaran pengetahuan masyarakat tentang pencegahan covid-19 di kecamatan padangsidimpuan batunadua, kota padangsidimpuan [Indonesian Health Scientific Journal]. Jurnal Kesehatan Ilmiah Indonesia. 2021;6(1):107–14.

[14] Biswas M, Rahaman S, Biswas TK, Haque Z, Ibrahim B. Association of sex, age, and comorbidities with mortality in COVID-19 patients: a systematic review and metaanalysis. Intervirology. 2020 Dec;64(1):1–12.

[15] Putri NA, Putra AE, Mariko R. Hubungan usia, Jenis kelamin dan gejala dengan kejadian COVID-19 di Sumatera Barat. Majalah Kedokteran Andalas. 2021;44(2):104– 11.

[16] Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020 Feb;395(10223):507–13.

[17] Isbaniah F, Susanto AD. Pneumonia corona virus infection disease-19 (COVID-19). Journal Of The Indonesian Medical Association. 2020;70(4):87–94.

[18] Sukmana M, Yuniarti FA. The pathogenesis characteristics and symptom of Covid-19 in the context of establishing a nursing diagnosis. Jurnal Kesehatan Pasak Bumi Kalimantan. 2020;3(1):21–8.

[19] Fahmia R, Helda H, Nursari AY. Lama Rawat Inap Pasien Terkonfirmasi COVID-19 di Rumah Sakit Universitas Indonesia dan Faktor yang Mempengaruhinya. Jurnal Epidemiologi Kesehatan Indonesia. 2022;6(1):1–12.

[20] Wahab R, Poli E, Sugeng C. Pneumonia Covid-19 dengan Gangguan Ginjal Akut. e-CliniC. 2021;9(1).

[21] Liu PP, Blet A, Smyth D, Li H. The science underlying COVID-19: implications for the cardiovascular system. Circulation. 2020 Jul;142(1):68–78.

[22] Tignanelli CJ, Ingraham NE, Sparks MA, Reilkoff R, Bezdicek T, Benson B, et al. Antihypertensive drugs and risk of COVID-19? Lancet Respir Med. 2020 May;8(5):e30–1.

[23] Pititto BA, Ferreira SR. Diabetes and covid-19: more than the sum of two morbidities. Rev Saude Publica. 2020;54:54.

[24] Marhl M, Grubelnik V, Magdič M, Markovič R. Diabetes and metabolic syndrome as risk factors for COVID-19. Diabetes Metab Syndr. 2020;14(4):671–7.